Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1–84

Reeve, 1980, Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial, Br. Med. J., 280, 1340, 10.1136/bmj.280.6228.1340 Fox, 2002, Developments in parathyroid hormone and related peptides as bone-formation agents, Curr. Opin. Pharmacol., 2, 338, 10.1016/S1471-4892(02)00154-6 Hodsman, 2005, Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use, Endocr. Rev., 26, 688, 10.1210/er.2004-0006 Neer, 2001, Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis, N. Engl. J. Med., 344, 1434, 10.1056/NEJM200105103441904 Greenspan, 2007, Effect of recombinant human parathyroid hormone (1–84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial, Ann. Intern. Med., 146, 326, 10.7326/0003-4819-146-5-200703060-00005 Bradbeer, 1992, Treatment of osteoporosis with parathyroid peptide (hPTH 1–34) and oestrogen: increase in volumetric density of iliac cancellous bone may depend on reduced trabecular spacing as well as increased thickness of packets of newly formed bone, Clin. Endocrinol. (Oxf), 37, 282, 10.1111/j.1365-2265.1992.tb02323.x Hodsman, 2000, Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1–34) therapy in women with severe osteoporosis, Bone, 27, 311, 10.1016/S8756-3282(00)00316-1 Dempster, 2001, Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study, J. Bone Miner. Res., 16, 1846, 10.1359/jbmr.2001.16.10.1846 Jiang, 2003, Recombinant human parathyroid hormone (1–34) [teriparatide] improves both cortical and cancellous bone structure, J. Bone Miner. Res., 18, 1932, 10.1359/jbmr.2003.18.11.1932 Fox, 2007, Treatment of skeletally-mature ovariectomized rhesus monkeys with parathyroid hormone 1–84 for 16 months increases bone formation and density and improves trabecular architecture and biomechanical properties at the lumbar spine, J. Bone Miner. Res., 22, 260, 10.1359/jbmr.061101 Fox, 2007, Effects of treatment of ovariectomized adult rhesus monkeys with parathyroid hormone 1–84 for 16 months on trabecular and cortical bone structure and biomechanical properties of the proximal femur, Calcif. Tissue Int., 81, 53, 10.1007/s00223-007-9036-y Hildebrand, 1997, Quantification of bone microarchitecture with the structure model index, Comput. Methods Biomech. Biomed. Eng., 1, 15, 10.1080/01495739708936692 Hildebrand, 1999, Direct three-dimensional morphometric analysis of human cancellous bone: microstructural data from spine, femur, iliac crest, and calcaneus, J. Bone Miner. Res., 14, 1167, 10.1359/jbmr.1999.14.7.1167 Parfitt, 1987, Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee, J. Bone Miner. Res., 2, 595, 10.1002/jbmr.5650020617 Marcus, 2003, The skeletal response to teriparatide is largely independent of age, initial bone density, and prevalent vertebral fractures in postmenopausal women with osteoporosis, J. Bone Miner. Res., 18, 18, 10.1359/jbmr.2003.18.1.18 Parisien, 1988, Trabecular architecture in iliac crest bone biopsies: intra-individual variability in structural parameters and changes with age, Bone, 9, 289, 10.1016/8756-3282(88)90012-9 Black, 2005, One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis, N. Engl. J. Med., 353, 555, 10.1056/NEJMoa050336 Fox, 2008, Effects of treatment with parathyroid hormone 1–84 on quantity and biomechanical properties of thoracic vertebral trabecular bone in ovariectomized rhesus monkeys, Calcif. Tissue Int., 82, 212, 10.1007/s00223-008-9108-7 Miller, 2008, Intratrabecular tunneling increases trabecular number throughout the skeleton of ovariectomized rhesus monkeys treated with parathyroid hormone 1–84, Bone, 42, 1175, 10.1016/j.bone.2008.01.029 Greenspan, 2006, Bone turnover markers and BMD remain elevated in postmenopausal osteoporotic women through a full 24 months of treatment with human parathyroid hormone 1–84 (PTH), J. Bone Miner. Res., 21, S114 Dobnig, 2005, Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy, J. Clin. Endocrinol. Metab., 90, 3970, 10.1210/jc.2003-1703 Lindsay, 2007, Effects of one-month treatment with PTH(1–34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium, J. Bone Miner. Res., 22, 495, 10.1359/jbmr.070104 Fox, 2007, Effects of daily treatment with parathyroid hormone 1–84 on density, architecture and biomechanical properties of cortical bone in adult ovariectomized rhesus monkeys, Bone, 41, 321, 10.1016/j.bone.2007.04.197 Bogado, 2006, Longitudinal changes in trabecular and cortical BMD and indices of bone strength assessed by quantitative computed tomography at the hip of postmenopausal osteoporotic women treated with parathyroid hormone (1–84) for 18 months, J. Bone Miner. Res., 21, S296 Burr, 2001, Intermittently administered human parathyroid hormone(1–34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys, J. Bone Miner. Res., 16, 157, 10.1359/jbmr.2001.16.1.157 Sato, 2004, Teriparatide [PTH(1–34)] strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity, J. Bone Miner. Res., 19, 623, 10.1359/JBMR.040112 Jerome, 2001, Treatment with human parathyroid hormone (1–34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fasicularis), Bone, 28, 150, 10.1016/S8756-3282(00)00430-0 Hodsman, 2003, Efficacy and safety of human parathyroid hormone-(1–84) in increasing bone mineral density in postmenopausal osteoporosis, J. Clin. Endocrinol. Metab., 88, 5212, 10.1210/jc.2003-030768 Lindsay, 2004, Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis, Arch. Intern. Med., 164, 2024, 10.1001/archinte.164.18.2024